Equity Overview
Price & Market Data
Price: $3.62
Daily Change: -$0.11 / 3.04%
Range: $3.60 - $3.75
Market Cap: $39,040,612
Volume: 14,801
Performance Metrics
1 Week: 3.72%
1 Month: -5.97%
3 Months: -13.19%
6 Months: 7.74%
1 Year: -36.71%
YTD: 13.48%
Company Details
Employees: 24
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Lantern Pharma Inc. focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process for developing cancer therapies and oncology drug. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.